Risk factor analysis of peripherally inserted central catheter-related venous thromboembolism in patients with hematological malignancies and establishment of a prediction model: A Prospective Cohort Study

For many people living with blood cancers, a thin, flexible tube called a peripherally inserted central catheter, or PICC, is a lifeline. This device is threaded through a vein in the arm and guided up to a large vessel near the heart, allowing doctors to deliver powerful medications, blood products, and nutrients without the pain of repeated needle sticks. While this tool is standard care in hematology centers, it carries a hidden danger. The presence of the tube, combined with the body's natural tendency to clot when fighting cancer or undergoing treatment, can sometimes cause a blood clot to form inside the vein around the catheter. This condition, known as catheter-related thrombosis, is more than just a minor inconvenience; it can block the tube, force its premature removal, or in severe cases, send a clot traveling to the lungs. Because patients with blood cancers already have a heightened risk of clotting, doctors have long sought a reliable way to predict who is most likely to develop these clots, hoping to intervene before trouble starts.

A team of researchers at Mianyang Central Hospital in China recently set out to solve this specific puzzle. They followed a group of 341 patients with various blood cancers who had just received a PICC line. Over the course of several years, the medical team watched closely, checking for signs of clots and gathering detailed information about each patient's health, their specific type of cancer, the treatments they received, and even specific proteins floating in their blood. The goal was to move beyond general guesses and find the exact combination of factors that signals a high risk for this complication. By the end of the study, they had identified a clear pattern: not all patients were at equal risk, and the danger could be spotted by looking at a specific set of clues.

The study revealed that the risk of developing a clot was not random. It was strongly linked to five specific factors. First, patients who were undergoing a procedure called autologous hematopoietic stem cell transplantation, where their own stem cells are collected and returned to the body after high-dose chemotherapy, faced a significantly higher risk. Second, the presence of high levels of C-reactive protein, a marker that indicates the body is fighting inflammation, was a warning sign. Third, the researchers found that elevated levels of two specific proteins in the blood—vascular endothelial growth factor, which helps blood vessels grow and repair, and soluble P-selectin, a molecule released when blood platelets are activated—were powerful indicators of danger. Finally, a standard risk assessment tool known as the Caprini score, which tallies up various health factors, proved to be a crucial part of the picture. When the researchers combined these five elements, they created a new prediction tool that could accurately identify patients who would develop clots.

This new tool, which the team built into a visual chart called a nomogram, performed with remarkable precision. In their testing, the model correctly identified 82 percent of the patients who actually developed clots and correctly ruled out clots in 89 percent of those who did not. This level of accuracy is significant because it suggests that doctors could use this chart to spot high-risk patients early. Instead of treating every patient the same, a doctor could look at a patient's specific blood markers and treatment history, plug those numbers into the model, and see a clear probability of risk. If a patient is flagged as high risk, the medical team could take extra precautions, such as closer monitoring or preventative measures, to protect the patient's vein and ensure their treatment continues without interruption.

The researchers were careful to note that their findings came from a single hospital in China, which means the results need to be tested in other places and with larger groups of people before they become a universal standard. They also pointed out that their study focused on patients receiving their own stem cells, so the model might need adjustment for those receiving stem cells from a donor. Despite these limitations, the study offers a concrete step forward. It moves the conversation from general worry about clotting to a specific, measurable understanding of who is most vulnerable. By combining what doctors already know about a patient's treatment with new insights from their blood chemistry, this work provides a clearer path toward safer care for some of the most vulnerable patients in the hospital.